

**Title:** Testosterone and longevity in men and women: A Mendelian randomization study in the UK Biobank

**Authors:** CM Schooling,<sup>1,2</sup> JV Zhao<sup>2</sup>

**Affiliations:**

1 City University of New York, Graduate School of Public Health and Health Policy, 55 West 125<sup>th</sup> St, New York 10027, NY, USA

2 School of Public Health, Li Ka Shing Faculty of Medicine, 7 Sassoon Road, Pokfulam, Hong Kong

Abstract: 244

Word count: 1953

Tables: 1

Supplementary Tables: 2

## **Abstract**

**Background:** After decades of rising life expectancy, life expectancy in the developed West is currently stagnated and remains shorter in men than women. Very well-established evolutionary biology theory suggests that lifespan trades off against reproductive success, possibly sex-specifically. We examined whether a key driver of reproductive success, testosterone, affected lifespan using a Mendelian randomization study of longevity in the UK Biobank to obtain unbiased estimates, along with control exposures.

**Methods:** We applied published genetic instruments for testosterone to obtain inverse variance weighted estimates of associations with longevity, proxied by survival to (i.e., age at) recruitment, in 167020 men and 194174 women. We similarly obtained estimates for smoking initiation, and absorbate, a marker of vitamin C metabolism, because. We also conducted sensitivity analysis.

**Results:** Overall testosterone was associated with poorer survival (0.10 years younger at recruitment per effect size of testosterone, 95% confidence interval (CI) 0.004 to 0.20). As expected, smoking initiation was also associated with poorer survival (0.37 years younger, 95% CI 0.25 to 0.50), but not absorbate (0.01 years younger, 95% CI -0.09 to 0.11). Sensitivity analysis generally gave a similar interpretation

**Conclusions:** Consistent, with well-established theory, testosterone reduced longevity. Several aspects of a healthy lifestyle (such as a low animal fat diet) and several widely used medications (such as statins, metformin, dexamethasone and possibly aspirin) happen to modulate testosterone. Explicitly designing interventions sex-specifically based on these insights might be a means of addressing stagnating life expectancy and sexual disparities in life expectancy.

Sexual dimorphism in lifespan is widely evident, including among humans, contemporaneously and historically.<sup>1,2</sup> Many reasons have been advanced for shorter life expectancy in men than women, from gendered health and health care seeking behavior<sup>3</sup> through sex-specific nutrient metabolism and steroid hormones<sup>4</sup> to sex-specific sexual selection pressures,<sup>5,6</sup> but few of these have been explicitly exploited as a means of promoting healthy aging in both sexes. As the long-term trend of increasing life expectancy in the West now appears to be stagnating,<sup>7</sup> reconsidering overlooked targets and their implications for the design of interventions might bear consideration.

An obvious modifiable difference between men and women is levels of sex hormones. Estrogen has been intensively investigated as a protective factor that might explain differences in longevity by sex. Observational evidence concerning benefits of exogenous estrogen in women was very promising.<sup>8</sup> Large-scale trials of estrogen in women and men were stopped early for harm or lack of benefit.<sup>9</sup> The discrepant findings have been ascribed to overlooked confounding by socio-economic position in the observational studies.<sup>9</sup> Promising observational evidence exists for longevity benefits of endogenous testosterone in women<sup>10-12</sup> and men.<sup>13</sup> Testosterone in men falls with aging and ill-health,<sup>14-16</sup> likely generating residual confounding, as health status is difficult to adjust for comprehensively. A trial of the cardiovascular safety of testosterone in women has been successfully conducted (<https://clinicaltrials.gov/ct2/show/NCT00612742>). A small trial of testosterone in frail older men was stopped early,<sup>17</sup> making it difficult to interpret. A larger trial of exogenous testosterone on cardiovascular disease is now underway in men (<https://clinicaltrials.gov/ct2/show/NCT03518034>). Theoretically, the expectation for effects of testosterone on health might be in a similar direction to those found for estrogen because of the well-established Darwinian evolutionary biology trade-off between reproduction, and its drivers, on the one hand, and longevity, on the other hand.<sup>18-20</sup> However, testosterone in humans could be an exception.

Here to clarify, we conducted a Mendelian randomization (MR) study of the effects of testosterone on longevity in men and women. MR studies take advantage of the random allocation of genetic material at conception to obtain unconfounded estimates.<sup>21</sup> Longevity studies compare characteristics of survivors to older ages with characteristics of younger people because lifetime harmful factors inevitably become less common with increasing age.<sup>22</sup> In contrast, observational prospective cohort studies comparing mortality incidence after recruitment are open to selection bias from any deaths prior to recruitment having already depleted the susceptibles<sup>23</sup> which may attenuate estimates even to the extent of suggesting no benefit of proven interventions.<sup>24</sup> As such,

longevity studies, take advantage of the changing structure of risk factors with age to obtain estimates of effects on mortality free from selection bias.<sup>25</sup> Smoking initiation was used as a positive control outcome because smoking is very well-known to be addictive and to substantially reduce longevity.<sup>26</sup> A marker of vitamin C metabolism, absorbate, was used as a negative control outcome because vitamin C is no longer thought to affect mortality.<sup>27</sup>

## Methods

### Data sources

The UK Biobank recruited half a million people intended to be aged 40 to 69 years from across Great Britain in 2006-10.<sup>28</sup> Average age is about 57 years and just over half the participants are women. We extracted overall and sex-specific genetic associations with age at recruitment from publicly available UK Biobank summary statistics in white British (<http://www.nealelab.is/uk-biobank>). These specific summary statistics were generated from linear regression adjusted for sex and the first 20 principal components, after excluding poor quality samples. Where relevant genetic information was not available from these summary statistics, we similarly generated corresponding information from the UK Biobank individual data.

### Exposures

We used published sex-specific genetic predictors of testosterone (125 variants for men and 254 for women).<sup>29</sup> We used published genetic predictors of smoking initiation (361 variants),<sup>30</sup> and of vitamin C metabolism (1 variant).<sup>31</sup>

### Outcome

In this longevity study, we used age at recruitment to the UK Biobank as a proxy for survival, as there is no particular reason, apart from prior death (i.e., lack of survival), why genetics should generate differences in willingness to participate by age. So, harmful exposures would be expected to be associated with younger age at recruitment.

### Statistical analysis

We obtained the F-statistics for the genetic instruments using an established approximation (square of genetic variant on exposure divided by its variance).<sup>32</sup> As F-statistic of 10 or less is usually taken as indicating a weak instrument. We aligned genetic associations on the same allele for exposures and outcome. We included palindromic and non-biallelic genetic variants because the genetic

associations with exposures and outcome were obtained in the same study or have been used in the same study. We used proxies, as necessary. We meta-analyzed genetic variant specific Wald estimates (ratio of genetic variant on outcome to genetic variant on exposure) using inverse variance weighting (IVW) with multiplicative random effects. IVW estimates assume balance pleiotropy.<sup>33</sup> We used estimates with different assumptions as sensitivity analysis. The weighted median has a majority valid assumption and assumes >50% of the genetic variants are valid instruments, while the contamination mixture method has a contrasting plurality valid assumption.<sup>33</sup> MR-Egger detects pleiotropic effects acting on the outcome other than via the exposure, but assumes that the genetic instruments do not act via confounders of exposure on outcome.<sup>32</sup> As previously, to avoid pleiotropic effects of sex hormone binding globulin, we used established genetic predictors of bio-available testosterone in men and total testosterone in women.<sup>34</sup> Bio-available testosterone may also be a more sensitive indicator than total testosterone of active testosterone in men.<sup>35</sup> Where necessary we combined estimates for men and women using IVW meta-analysis.

We used the MendelianRandomization R package to obtain estimates. We did not adjust for multiple comparisons because this is a hypothesis driven study addressing one question with the use of control exposures, both positive and negative. This study only uses publicly available summary associations from the UK Biobank supplemented by individual level data for information not included in the publicly available summary statistics which was obtained under applicant number 42468. The UK Biobank has ethics approval from the North West Multi-centre Research Ethics Committee. All participants gave informed consent.

## Results

In total 167020 men and 194174 women from the UK Biobank were included. Almost all genetic variants for the exposures were available for the outcome, just two variants for smoking initiation were replaced by highly correlated ( $r^2 > 0.9$ ) variants (rs2587507 replaced by rs745571, and rs2359180 by rs768576) obtained from LDlink (<https://ldlink.nci.nih.gov/>). The average F-statistic for testosterone was 128.6 in men and 83.6 in women, and for smoking initiation was 44.9. As expected, smoking initiation was associated with younger age at recruitment (Table 1), corresponding to poorer survival. Similarly, as expected absorbate was unrelated to age at recruitment (Table 1). Overall, testosterone was associated with younger age at recruitment, i.e., poorer survival (Table 1), with slightly larger estimates in men than women (Table S1). Estimates were similar in sensitivity

analysis using age at recruitment as a categorical variable (age 60 years or less) (Table S2) and using sensitivity analysis (Table S1).

## Discussion

Despite observational studies suggesting that testosterone might promote longevity,<sup>10-13</sup> our study with greater robustness to confounding and selection bias, consistent with theoretical expectations from evolutionary biology,<sup>18 19</sup> suggests that testosterone reduces longevity. Our study also showed smoking initiation reduced survival as would be expected.<sup>26</sup>

Our findings differ from previous observational studies which suggest that endogenous testosterone might improve longevity.<sup>10-13</sup> However, these studies are open to both confounding by health status<sup>14 15</sup> and selection bias from inevitably only recruiting survivors.<sup>23</sup> Our findings are more consistent with previous MR studies suggesting exogenous testosterone increases cardiovascular disease,<sup>36 37</sup> and corresponding warnings from regulators (<https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-cautions-about-using-testosterone-products-low-testosterone-due>).

Several potential mechanisms could underlie our findings. Experimental studies suggest testosterone increases coronary plaque volume<sup>38</sup> and coagulation<sup>39</sup> while impairing endothelial function.<sup>40-42</sup> Testosterone increases vulnerability to hormone related cancers, including prostate cancer,<sup>29</sup> breast cancer<sup>29</sup> and endometrial cancer.<sup>29</sup> Testosterone is also increasingly acknowledged to be an immune-suppressant,<sup>43</sup> potentially increasing susceptibility to cancer,<sup>44</sup> as well as to infectious diseases,<sup>43</sup> such as COVID-19. Testosterone also may also induce impulsive behaviour.<sup>45</sup>

## Relevance to interventions

Given the importance of testosterone to reproductive success, testosterone is likely responsive to environmental indicators of suitable conditions for procreation, and hence a modifiable target of intervention. Serendipitously, many aspects of a healthy lifestyle and several widely used interventions reduce testosterone. A healthy diet, i.e., low-fat, high fiber, high soy, and low animal fat reduces testosterone in men<sup>46-48</sup> and women.<sup>49</sup> Exercise and weight loss reduce testosterone in women,<sup>50-52</sup> but possibly less so in men,<sup>53 54</sup> although severe calorie restriction reduces testosterone in men.<sup>55</sup> One of the most effective medications for preventing and treating cardiovascular disease, i.e., statins, reduces testosterone in men and women.<sup>56</sup> The first-line treatment for diabetes, metformin, may reduce testosterone in women,<sup>57</sup> but not men.<sup>58</sup> Aspirin may also reduce

testosterone.<sup>59</sup> Another essential medicine, dexamethasone reduces testosterone.<sup>60 61</sup> As such, many current interventions to promote longevity do happen to reduce testosterone, particularly in women. Explicitly, searching sex-specifically for interventions based on this insight might facilitate the search for new means of promoting healthy aging, identify at an early stage any potential interventions that are likely to be unsuccessful, and identify where interventions should be sex-specific.

#### Limitations

Although this study used an innovative approach to generate an unbiased assessment of the effect of testosterone on longevity, it has several limitations. First, MR has stringent assumptions including that the genetic instruments predict the exposures, hence our use of published instruments,<sup>29-31</sup> that the instruments are independent of exposure outcome confounders, which stems from the use of genetic instruments not related to confounders such as health status, lifestyle and socioeconomic position, and that the instruments only affect the outcome via the exposure, hence our use of sensitivity analysis and control exposures. Second, we assumed a linear relation of survival with age when it is exponential. However, at the relatively young ages considered here such an approximation is less of an issue than in old age. A sensitivity analysis using survival to age 60 years as the outcome gave a similar interpretation for genetically predicted testosterone (Table S2). Third, the samples used for exposures and outcome overlap. However, that would be expected to bias towards the null,<sup>62</sup> so our estimates may be conservative. Moreover, the potential bias is less of concern as we did not use weak instruments to predict exposures.<sup>62</sup> Fourth, our study gives lifetime effects of endogenous testosterone up to age ~57 years rather than the effect of an intervention. However, the estimates for testosterone can be contextualized by the estimates for smoking. Fifth, longevity studies have been criticized for not taking account of cohort effects.<sup>25</sup> However, there is no reason to think that genetics are susceptible to cohort effects in the UK Biobank. Sixth, canalization, i.e., compensation for genetic effects might exist. However, this would likely bias towards the null. Seventh, the UK Biobank is not a population representative study. However, we used a study of longevity rather than a traditional prospective cohort study to avoid selection bias. Eighth, the relatively young age at recruitment, and correspondingly high survival means this study lacks power, so we focused on major determinants of longevity, but were not able to ascertain if the effects of testosterone were greater in men than women. Ninth, the effects of testosterone may vary by age. However, causes are generally expected to act consistently, although they may not be relevant in all situations.<sup>63</sup> Testosterone in men falls with age,<sup>16</sup> so our findings could be relatively less relevant to older men, but absolute risk of death increases with age.

## Conclusion

Consistent with well-established evolutionary biology theory<sup>18-20</sup> testosterone appeared to reduce lifespan. Serendipitously, many existing strategies for promoting health reduce testosterone, particularly in women. Explicitly using an established theory as a guide might facilitate the search for new interventions, and draws attention to the importance of sex-specific interventions.

**Acknowledgements:** We are immensely grateful to all those who contributed to the UK Biobank study. We are also grateful to Ben Neale for making UK Biobank genetic summary statistics publicly available.

**Contributorship:** CMS designed the study, conducted the analysis and wrote the first draft. JVZ reviewed and advised on the study design, generated estimates for the individual data from the UK Biobank, checked the analysis and advised on the interpretation.

## References

1. Lemaître JF, Ronget V, Tidière M, et al. Sex differences in adult lifespan and aging rates of mortality across wild mammals. *Proc Natl Acad Sci U S A* 2020;117(15):8546-53. doi: 10.1073/pnas.1911999117 [published Online First: 2020/03/25]
2. Zarulli V, Barthold Jones JA, Oksuzyan A, et al. Women live longer than men even during severe famines and epidemics. *Proc Natl Acad Sci U S A* 2018;115(4):E832-e40. doi: 10.1073/pnas.1701535115 [published Online First: 2018/01/10]
3. Bartz D, Chitnis T, Kaiser UB, et al. Clinical Advances in Sex- and Gender-Informed Medicine to Improve the Health of All: A Review. *JAMA Intern Med* 2020 doi: 10.1001/jamainternmed.2019.7194 [published Online First: 2020/02/11]
4. Regan JC, Partridge L. Gender and longevity: why do men die earlier than women? Comparative and experimental evidence. *Best Pract Res Clin Endocrinol Metab* 2013;27(4):467-79. doi: 10.1016/j.beem.2013.05.016 [published Online First: 2013/09/24]
5. Schooling CM. Could androgens be relevant to partly explain why men have lower life expectancy than women? *J Epidemiol Community Health* 2016;70(4):324-8. doi: 10.1136/jech-2015-206336 [published Online First: 2015/12/15]
6. Gardner EJ, Neville MDC, Samocha KE, et al. Sex-biased reduction in reproductive success drives selective constraint on human genes. *bioRxiv*; doi: <https://doi.org/10.1101/20200526116111> 2020
7. Lopez AD, Adair T. Is the long-term decline in cardiovascular-disease mortality in high-income countries over? Evidence from national vital statistics. *International journal of epidemiology* 2019;48(6):1815-23. doi: 10.1093/ije/dyz143 [published Online First: 2019/08/06]
8. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. *Prev Med* 1991;20(1):47-63. doi: 10.1016/0091-7435(91)90006-p [published Online First: 1991/01/01]



9. Petitti D. Commentary: hormone replacement therapy and coronary heart disease: four lessons. *International journal of epidemiology* 2004;33(3):461-3. doi: 10.1093/ije/dyh192 [published Online First: 2004/05/29]
10. Schaffrath G, Kische H, Gross S, et al. Association of sex hormones with incident 10-year cardiovascular disease and mortality in women. *Maturitas* 2015;82(4):424-30. doi: 10.1016/j.maturitas.2015.08.009 [published Online First: 2015/09/20]
11. Benn M, Voss SS, Holmegard HN, et al. Extreme concentrations of endogenous sex hormones, ischemic heart disease, and death in women. *Arterioscler Thromb Vasc Biol* 2015;35(2):471-7. doi: 10.1161/atvbaha.114.304821 [published Online First: 2015/01/01]
12. Sievers C, Klotsche J, Pieper L, et al. Low testosterone levels predict all-cause mortality and cardiovascular events in women: a prospective cohort study in German primary care patients. *Eur J Endocrinol* 2010;163(4):699-708. doi: 10.1530/eje-10-0307 [published Online First: 2010/08/06]
13. Araujo AB, Dixon JM, Suarez EA, et al. Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis. *The Journal of clinical endocrinology and metabolism* 2011;96(10):3007-19. doi: 10.1210/jc.2011-1137 [published Online First: 2011/08/06]
14. Gagnon SS, Nindl BC, Vaara JP, et al. Basal Endogenous Steroid Hormones, Sex Hormone-Binding Globulin, Physical Fitness, and Health Risk Factors in Young Adult Men. *Front Physiol* 2018;9:1005. doi: 10.3389/fphys.2018.01005 [published Online First: 2018/08/14]
15. Yeap BB. Hormones and health outcomes in aging men. *Experimental gerontology* 2013;48(7):677-81. doi: 10.1016/j.exger.2012.07.012 [published Online First: 2012/08/14]
16. Haring R, Hannemann A, John U, et al. Age-specific reference ranges for serum testosterone and androstenedione concentrations in women measured by liquid chromatography-tandem mass spectrometry. *The Journal of clinical endocrinology and metabolism* 2012;97(2):408-15. doi: 10.1210/jc.2011-2134 [published Online First: 2011/12/14]
17. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. *The New England journal of medicine* 2010;363(2):109-22. doi: 10.1056/NEJMoa1000485 [published Online First: 2010/07/02]
18. Brooks RC, Garratt MG. Life history evolution, reproduction, and the origins of sex-dependent aging and longevity. *Ann N Y Acad Sci* 2017;1389(1):92-107. doi: 10.1111/nyas.13302 [published Online First: 2016/12/23]
19. Stearns SC. Issues in evolutionary medicine. *Am J Hum Biol* 2005;17(2):131-40. doi: 10.1002/ajhb.20105 [published Online First: 2005/03/01]
20. Wells JCK, Nesse RM, Sear R, et al. Evolutionary public health: introducing the concept. *Lancet (London, England)* 2017;390(10093):500-09. doi: 10.1016/s0140-6736(17)30572-x [published Online First: 2017/08/10]
21. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? *International journal of epidemiology* 2003;32(1):1-22. doi: 10.1093/ije/dyg070 [published Online First: 2003/04/12]

22. Heijmans BT, Westendorp RG, Slagboom PE. Common gene variants, mortality and extreme longevity in humans. *Exp Gerontol* 2000;35(6-7):865-77. doi: 10.1016/s0531-5565(00)00171-6 [published Online First: 2000/10/29]
23. Glymour MM. Using causal diagrams to understand common problems in social epidemiology. San Francisco: Jossey-Bass 2006.
24. MacLaughlin EJ, Ernst ME. From Clinical Trials to Bedside: the Use of Antihypertensives in Aged Individuals. Part 1: Evaluation and Evidence of Treatment Benefit. *Curr Hypertens Rep* 2019;21(11):82. doi: 10.1007/s11906-019-0987-y [published Online First: 2019/10/11]
25. Lewis SJ, Brunner EJ. Methodological problems in genetic association studies of longevity--the apolipoprotein E gene as an example. *Int J Epidemiol* 2004;33(5):962-70. doi: 10.1093/ije/dyh214 [published Online First: 2004/08/21]
26. Jha P, Ramasundarahettige C, Landsman V, et al. 21st-century hazards of smoking and benefits of cessation in the United States. *The New England journal of medicine* 2013;368(4):341-50. doi: 10.1056/NEJMsa1211128 [published Online First: 2013/01/25]
27. Bjelakovic G, Nikolova D, Gluud LL, et al. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. *The Cochrane database of systematic reviews* 2012(3):CD007176. doi: 10.1002/14651858.CD007176.pub2 [published Online First: 2012/03/16]
28. Collins R. What makes UK Biobank special? *Lancet (London, England)* 2012;379(9822):1173-4. doi: 10.1016/s0140-6736(12)60404-8 [published Online First: 2012/04/03]
29. Ruth KS, Day FR, Tyrrell J, et al. Using human genetics to understand the disease impacts of testosterone in men and women. *Nat Med* 2020;26(2):252-58. doi: 10.1038/s41591-020-0751-5 [published Online First: 2020/02/12]
30. Larsson SC, Mason AM, Bäck M, et al. Genetic predisposition to smoking in relation to 14 cardiovascular diseases. *European heart journal* 2020 doi: 10.1093/eurheartj/ehaa193 [published Online First: 2020/04/18]
31. Ravindran RD, Sundaresan P, Krishnan T, et al. Genetic variants in a sodium-dependent vitamin C transporter gene and age-related cataract. *Br J Ophthalmol* 2019;103(9):1223-27. doi: 10.1136/bjophthalmol-2018-312257 [published Online First: 2018/11/18]
32. Bowden J, Del Greco MF, Minelli C, et al. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I<sup>2</sup> statistic. *International journal of epidemiology* 2016;45(6):1961-74. doi: 10.1093/ije/dyw220 [published Online First: 2016/09/13]
33. Slob EAW, Burgess S. A comparison of robust Mendelian randomization methods using summary data. *Genetic epidemiology* 2020 doi: 10.1002/gepi.22295 [published Online First: 2020/04/07]
34. Zhao JV, Schooling CM. The role of testosterone in chronic kidney disease and kidney function in men and women: a bi-directional Mendelian randomization study in the UK Biobank. *BMC Med* 2020;18(1):122. doi: 10.1186/s12916-020-01594-x [published Online First: 2020/06/05]
35. Keevil BG, Adaway J. Assessment of free testosterone concentration. *J Steroid Biochem Mol Biol* 2019;190:207-11. doi: 10.1016/j.jsbmb.2019.04.008 [published Online First: 2019/04/11]

36. Schooling CM, Luo S, Au Yeung SL, et al. Genetic predictors of testosterone and their associations with cardiovascular disease and risk factors: A Mendelian randomization investigation. *Int J Cardiol* 2018;267:171-76. doi: 10.1016/j.ijcard.2018.05.051 [published Online First: 2018/05/29]
37. Luo S, Au Yeung SL, Zhao JV, et al. Association of genetically predicted testosterone with thromboembolism, heart failure, and myocardial infarction: mendelian randomisation study in UK Biobank. *Bmj* 2019;364:l476. doi: 10.1136/bmj.l476 [published Online First: 2019/03/08]
38. Budoff MJ, Ellenberg SS, Lewis CE, et al. Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone. *Jama* 2017;317(7):708-16. doi: 10.1001/jama.2016.21043 [published Online First: 2017/02/28]
39. Ajayi AA, Halushka PV. Castration reduces platelet thromboxane A2 receptor density and aggregability. *QJM : monthly journal of the Association of Physicians* 2005;98(5):349-56. doi: 10.1093/qjmed/hci054 [published Online First: 2005/04/12]
40. Herman SM, Robinson JT, McCredie RJ, et al. Androgen deprivation is associated with enhanced endothelium-dependent dilatation in adult men. *Arterioscler Thromb Vasc Biol* 1997;17(10):2004-9. doi: 10.1161/01.atv.17.10.2004 [published Online First: 1997/11/14]
41. McCredie RJ, McCrohon JA, Turner L, et al. Vascular reactivity is impaired in genetic females taking high-dose androgens. *J Am Coll Cardiol* 1998;32(5):1331-5. doi: 10.1016/s0735-1097(98)00416-1 [published Online First: 1998/11/11]
42. van Kesteren PJ, Kooistra T, Lansink M, et al. The effects of sex steroids on plasma levels of marker proteins of endothelial cell functioning. *Thromb Haemost* 1998;79(5):1029-33. [published Online First: 1998/06/03]
43. Jaillon S, Berthenet K, Garlanda C. Sexual Dimorphism in Innate Immunity. *Clin Rev Allergy Immunol* 2019;56(3):308-21. doi: 10.1007/s12016-017-8648-x [published Online First: 2017/10/01]
44. Schooling CM, Zhao JV. Strengthening the immune system for cancer prevention. *Proc Natl Acad Sci U S A* 2018;115(19):E4316-e17. doi: 10.1073/pnas.1802584115 [published Online First: 2018/04/20]
45. Wu Y, Shen B, Liao J, et al. Single dose testosterone administration increases impulsivity in the intertemporal choice task among healthy males. *Horm Behav* 2020;118:104634. doi: 10.1016/j.yhbeh.2019.104634 [published Online First: 2019/11/26]
46. Gardner-Thorpe D, O'Hagen C, Young I, et al. Dietary supplements of soya flour lower serum testosterone concentrations and improve markers of oxidative stress in men. *Eur J Clin Nutr* 2003;57(1):100-6. doi: 10.1038/sj.ejcn.1601495 [published Online First: 2003/01/28]
47. Wang C, Catlin DH, Starcevic B, et al. Low-fat high-fiber diet decreased serum and urine androgens in men. *The Journal of clinical endocrinology and metabolism* 2005;90(6):3550-9. doi: 10.1210/jc.2004-1530 [published Online First: 2005/03/03]
48. Habito RC, Ball MJ. Postprandial changes in sex hormones after meals of different composition. *Metabolism* 2001;50(5):505-11. doi: 10.1053/meta.2001.20973 [published Online First: 2001/04/25]
49. Berrino F, Bellati C, Secreto G, et al. Reducing bioavailable sex hormones through a comprehensive change in diet: the diet and androgens (DIANA) randomized trial.

- Cancer Epidemiol Biomarkers Prev* 2001;10(1):25-33. [published Online First: 2001/02/24]
50. van Gemert WA, Schuit AJ, van der Palen J, et al. Effect of weight loss, with or without exercise, on body composition and sex hormones in postmenopausal women: the SHAPE-2 trial. *Breast Cancer Res* 2015;17(1):120. doi: 10.1186/s13058-015-0633-9 [published Online First: 2015/09/04]
51. Haqq L, McFarlane J, Dieberg G, et al. Effect of lifestyle intervention on the reproductive endocrine profile in women with polycystic ovarian syndrome: a systematic review and meta-analysis. *Endocr Connect* 2014;3(1):36-46. doi: 10.1530/ec-14-0010 [published Online First: 2014/02/04]
52. Campbell KL, Foster-Schubert KE, Alfano CM, et al. Reduced-calorie dietary weight loss, exercise, and sex hormones in postmenopausal women: randomized controlled trial. *J Clin Oncol* 2012;30(19):2314-26. doi: 10.1200/jco.2011.37.9792 [published Online First: 2012/05/23]
53. Moran LJ, Brinkworth GD, Martin S, et al. Long-Term Effects of a Randomised Controlled Trial Comparing High Protein or High Carbohydrate Weight Loss Diets on Testosterone, SHBG, Erectile and Urinary Function in Overweight and Obese Men. *PLoS One* 2016;11(9):e0161297. doi: 10.1371/journal.pone.0161297 [published Online First: 2016/09/02]
54. Hayes LD, Elliott BT. Short-Term Exercise Training Inconsistently Influences Basal Testosterone in Older Men: A Systematic Review and Meta-Analysis. *Front Physiol* 2018;9:1878. doi: 10.3389/fphys.2018.01878 [published Online First: 2019/01/30]
55. Muller MJ, Enderle J, Pourhassan M, et al. Metabolic adaptation to caloric restriction and subsequent refeeding: the Minnesota Starvation Experiment revisited. *The American journal of clinical nutrition* 2015;102(4):807-19. doi: 10.3945/ajcn.115.109173 [published Online First: 2015/09/25]
56. Schooling CM, Au Yeung SL, Freeman G, et al. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. *BMC Med* 2013;11:57. doi: 10.1186/1741-7015-11-57 [published Online First: 2013/03/02]
57. Barba M, Schünemann HJ, Sperati F, et al. The effects of metformin on endogenous androgens and SHBG in women: a systematic review and meta-analysis. *Clinical endocrinology* 2009;70(5):661-70. doi: 10.1111/j.1365-2265.2008.03459.x [published Online First: 2009/01/31]
58. Casulari LA, Caldas AD, Domingues Casulari Motta L, et al. Effects of metformin and short-term lifestyle modification on the improvement of male hypogonadism associated with metabolic syndrome. *Minerva Endocrinol* 2010;35(3):145-51. [published Online First: 2010/10/13]
59. Conte D, Romanelli F, Fillo S, et al. Aspirin inhibits androgen response to chorionic gonadotropin in humans. *Am J Physiol* 1999;277(6):E1032-7. doi: 10.1152/ajpendo.1999.277.6.E1032 [published Online First: 1999/12/22]
60. Vanky E, Salvesen KA, Carlsen SM. Six-month treatment with low-dose dexamethasone further reduces androgen levels in PCOS women treated with diet and lifestyle advice, and metformin. *Hum Reprod* 2004;19(3):529-33. doi: 10.1093/humrep/deh103 [published Online First: 2004/03/05]

61. Doerr P, Pirke KM. Dexamethasone-induced suppression of the circadian rhythm of plasma testosterone in normal adult males. *J Steroid Biochem* 1979;10(1):81-6. doi: 10.1016/0022-4731(79)90145-6 [published Online First: 1979/01/01]
62. Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-sample Mendelian randomization. *Genetic epidemiology* 2016;40(7):597-608. doi: 10.1002/gepi.21998 [published Online First: 2016/10/19]
63. Lopez PM, Subramanian SV, Schooling CM. Effect measure modification conceptualized using selection diagrams as mediation by mechanisms of varying population-level relevance. *J Clin Epidemiol* 2019;113:123-28. doi: 10.1016/j.jclinepi.2019.05.005 [published Online First: 2019/05/24]

**Table 1: Differences in age at recruitment to the UK Biobank for published genetic predictors of testosterone,<sup>29</sup> smoking,<sup>30</sup> and vitamin C (absorbate)<sup>31</sup> using Mendelian Randomization inverse variance weighted estimates**

Exposure type	Exposure	Years younger at recruitment	95% CI	p-value
Positive control	Smoking initiation compared to not	-0.37	-0.50 to -0.25	5.2e-9
Negative control	Absorbate (rs33972313)	-0.01	-0.11 to 0.09	0.79
Exposure	Testosterone (standard deviation)	-0.10	-0.20 to -0.004	0.04

## Supplementary Tables

**Supplementary Table 1: Differences in age at recruitment to the UK Biobank for published genetic predictors of testosterone<sup>29</sup> and smoking<sup>30</sup> using additional Mendelian Randomization analyses**

Exposure	Method	Subgroup	Years younger at recruitment	95% CI	P-value	Intercept	Q (p-value)		
Smoking (361 variants)	WM	all	-0.35	-0.52 to -0.17	0.0001	0.83	434.4 (0.004)		
	MR Egger	all	-0.32	-0.84 to 0.21	0.24				
	Conmix	all	-0.61	-0.94 to -0.34	0.0003				
Testosterone (125 variants for men, 254 variants for women)	IVW	Men	-0.12	-0.29 to 0.05	0.16	0.47	154.2 (0.03)		
		Women	-0.09	-0.22 to 0.03	0.14				
	WM	Men	-0.25	-0.54 to 0.04	0.09				
		Women	-0.28	-0.51 to -0.05	0.02				
	MR-Egger	all	-0.27	-0.45 to -0.09	0.003			0.72	262.1 (0.32)
		Men	-0.20	-0.48 to 0.07	0.15				
		Women	-0.13	-0.35 to 0.10	0.27				
	Conmix	All	-0.16	-0.33 to 0.02	0.08				
		Men	-0.34	-0.59 to -0.01	0.049				
Women		-0.12	-0.28 to 0.05	0.16					
		All	-0.17	-0.32 to -0.02	0.03				

WM: weighted median, IVW: inverse variance weighted, Conmix: contamination mixture model

**Supplementary Table 2: Recruitment to the UK Biobank at age 60+ years compared to younger than or equal to 60 years for genetically predicted testosterone<sup>29</sup> using Mendelian Randomization inverse variance weighting estimates**

	Odds ratio	95% CI	p-value
All	0.98	0.95 to 0.99	0.049
Men	0.97	0.93 to 1.01	0.13
Women	0.98	0.95 to 1.01	0.20